Metabolic acidosis | |
---|---|
![]() | |
The level of bicarbonate in the blood (HCO3−) determines the severity of acidosis. Bicarbonate measurements are part of routine metabolic panels. | |
Specialty | Nephrology |
Complications | Acute: poor morbidity and mortality outcomes; Chronic: adverse outcomes on kidney function, musculoskeletal system, possible cardiovascular effects |
Types | Acute Metabolic Acidosis Chronic Metabolic Acidosis |
Causes | Acute: Excessive amounts of organic acids; Chronic: Impaired kidney function |
Diagnostic method | Level of bicarbonate (HCO3-) in the blood |
Treatment | Acute: IV bicarbonate therapy;[1] Chronic: Diet rich in fruits and vegetables, oral alkali therapy[2] |
Frequency | Acute: Most often presented during critical illnesses, and hospitalizations: incidence ranging from 14-42%. [3][4] Chronic: Highly prevalent in people with Chronic Kidney Disease: 9.4% CKD Stage 3a; 18.1% CKD Stage 3b; 31.5% CKD Stage 4 and 5 [5] |
Metabolic acidosis is a serious electrolyte disorder characterized by an imbalance in the body's acid-base balance. Metabolic acidosis has three main root causes: increased acid production, loss of bicarbonate, and a reduced ability of the kidneys to excrete excess acids.[6] Metabolic acidosis can lead to acidemia, which is defined as arterial blood pH that is lower than 7.35.[7] Acidemia and acidosis are not mutually exclusive – pH and hydrogen ion concentrations also depend on the coexistence of other acid-base disorders; therefore, pH levels in people with metabolic acidosis can range from low to high.
Acute metabolic acidosis, lasting from minutes to several days, often occurs during serious illnesses or hospitalizations, and is generally caused when the body produces an excess amount of organic acids (ketoacids in ketoacidosis, or lactic acid in lactic acidosis). A state of chronic metabolic acidosis, lasting several weeks to years, can be the result of impaired kidney function (chronic kidney disease) and/or bicarbonate wasting. The adverse effects of acute versus chronic metabolic acidosis also differ, with acute metabolic acidosis impacting the cardiovascular system in hospital settings, and chronic metabolic acidosis affecting muscles, bones, kidney and cardiovascular health.[8]
Signs and symptoms
Acute metabolic acidosis
Symptoms are not specific, and diagnosis can be difficult unless patients present with clear indications for arterial blood gas sampling. Symptoms may include palpitations, headache, altered mental status such as severe anxiety due to hypoxia, decreased visual acuity, nausea, vomiting, abdominal pain, altered appetite and weight gain, muscle weakness, bone pain, and joint pain. People with acute metabolic acidosis may exhibit deep, rapid breathing called Kussmaul respirations which is classically associated with diabetic ketoacidosis.[9] Rapid deep breaths increase the amount of carbon dioxide exhaled, thus lowering the serum carbon dioxide levels, resulting in some degree of compensation. Overcompensation via respiratory alkalosis to form an alkalemia does not occur.
Extreme acidemia can also lead to neurological and cardiac complications:
- Neurological: lethargy, stupor, coma, seizures
- Cardiac: Abnormal heart rhythms (e.g., ventricular tachycardia) and decreased response to epinephrine, both leading to low blood pressure
Physical examination can occasionally reveal signs of the disease, but is often otherwise normal. Cranial nerve abnormalities are reported in ethylene glycol poisoning, and retinal edema can be a sign of methanol intoxication.
Chronic metabolic acidosis
Chronic metabolic acidosis has non-specific clinical symptoms but can be readily diagnosed by testing serum bicarbonate levels in patients with Chronic Kidney Disease (CKD) as part of a comprehensive metabolic panel. Patients with CKD Stages G3-G5 should be routinely screened for metabolic acidosis.[10][11]
Diagnostic approach and causes
Metabolic acidosis is defined as a reduced serum pH, and an abnormal serum bicarbonate concentration of <22 mEq/L, below the normal range of 22 to 29 mEq/L. However, if a patient has other coexisting acid-base disorders, the pH level may be low, normal or high in the setting of metabolic acidosis.[6] In the absence of chronic respiratory alkalosis, metabolic acidosis can be clinically diagnosed by measuring serum bicarbonate levels in the blood, which is generally a standard component of blood panels. Imperatively, when weighing a metabolic acidosis diagnosis, the change in serum bicarbonate levels over time should be considered; if baseline bicarbonate results are unknown, a single set of values may be misinterpreted.
Causes
Generally, metabolic acidosis occurs when the body produces too much acid (e.g., lactic acidosis, see below section), there is a loss of bicarbonate from the blood, or when the kidneys are not removing enough acid from the body.
Chronic metabolic acidosis is most often caused by a decreased capacity of the kidneys to excrete excess acids through renal ammoniagenesis. The typical Western diet generates 75-100 mEq of acid daily,[12] and individuals with normal kidney function increase the production of ammonia to get rid of this dietary acid. As kidney function declines, the tubules lose the ability to excrete excess acid, and this results in buffering of acid using serum bicarbonate, as well as bone and muscle stores.[13]
There are many causes of acute metabolic acidosis, and thus it is helpful to group them by the presence or absence of a normal anion gap.[14]
Increased anion gap
Causes of increased anion gap include:
- Lactic acidosis[15]
- Ketoacidosis (e.g., Diabetic, alcoholic, or starvation)[16]
- Chronic kidney failure[17]
- Transient 5-oxoprolinemia due to long-term ingestion of high-doses of acetaminophen (often seen with sepsis, liver failure, kidney failure, or malnutrition)[18]
- Intoxication:
- Salicylates, methanol, ethylene glycol[16]
- Organic acids, paraldehyde, ethanol, formaldehyde[19]
- Carbon monoxide, cyanide, ibuprofen, metformin[20]
- Propylene glycol (metabolized to L and D-lactate and is often found in infusions for certain intravenous medications used in the intensive care unit)[21]
- Massive rhabdomyolysis[22]
- Isoniazid, iron, phenelzine, tranylcypromine, valproic acid, verapamil[23]
- Topiramate
- Sulfates[24]
Normal anion gap
Causes of normal anion gap include[25]
- Inorganic acid addition
- Infusion/ingestion of HCl, NH
4Cl
- Infusion/ingestion of HCl, NH
- Gastrointestinal base loss
- Diarrhea
- Small bowel fistula/drainage
- Surgical diversion of urine into gut loops
- Renal base loss/acid retention:
- Hyperalimentation
- Addison disease
- Acetazolamide
- Spironolactone
- Saline infusion
To distinguish between the main types of metabolic acidosis, a clinical tool called the anion gap is considered very useful. It is calculated by subtracting the sum of the chloride and bicarbonate levels from the sum of the sodium and potassium levels. As sodium is the main extracellular cation, and chloride and bicarbonate are the main anions, the result should reflect the remaining anions. Normally, this concentration is about 8–16 mmol/L (12±4). An elevated anion gap (i.e. > 16 mmol/L) can indicate particular types of metabolic acidosis, such as types caused by certain poisons, lactate acidosis, and ketoacidosis. It is important to note that the anion gap can be spuriously normal in sampling errors of the sodium level, e.g. in extreme hypertriglyceridemia. The anion gap can also be increased due to relatively low levels of cations other than sodium and potassium (e.g. calcium or magnesium).[6]
As a differential diagnosis is made, other tests may be necessary, including toxicological screening and imaging of the kidneys, along with testing of electrolytes (including chloride), glucose, kidney function, and a full blood count. Urinalysis can reveal acidity (salicylate poisoning) or alkalinity (renal tubular acidosis type I). In addition, it can show ketones in ketoacidosis.[8] It is also important to differentiate between acidosis-induced hyperventilation and asthma; otherwise, treatment could lead to inappropriate bronchodilation.[26]
Pathophysiology
Compensatory mechanisms
Metabolic acidosis is characterized by a low concentration of bicarbonate (HCO−
3), which can happen with increased generation of acids (such as ketoacids or lactic acid), excess loss of HCO−
3 by the kidneys or gastrointestinal tract, or an inability to generate sufficient HCO−
3.[27] Thus demonstrating the importance of maintaining balance between acids and bases in the body for maintaining optimal functioning of organs, tissues and cells.
The body regulates the acidity of the blood by four buffering mechanisms.
- Bicarbonate buffering system
- Intracellular buffering by absorption of hydrogen atoms by various molecules, including proteins, phosphates and carbonate in bone.
- Respiratory compensation. Hyperventilation will cause more carbon dioxide to be removed from the body and thereby increases pH.
- Kidney compensation
Buffer
The decreased bicarbonate that distinguishes metabolic acidosis is therefore due to two separate processes: the buffer (from water and carbon dioxide) and additional renal generation. The buffer reactions are:
The Henderson-Hasselbalch equation mathematically describes the relationship between blood pH and the components of the bicarbonate buffering system:
- Using Henry's law, we can say that [CO2] = 0.03 × PaCO2
- (PaCO2 is the pressure of CO2 in arterial blood)
- Adding the other normal values, we get
Consequences
Acute Metabolic Acidosis
Acute Metabolic Acidosis most often occurs during hospitalizations, and acute critical illnesses. It is often associated with poor prognosis, with a mortality rate as high as 57% if the pH remains untreated at 7.20.[28] At lower pH levels, acute metabolic acidosis can lead to impaired circulation and end organ function.
Chronic Metabolic Acidosis
Chronic metabolic acidosis commonly occurs in people with Chronic Kidney Disease with an eGFR of less than 45 ml/min/1.73m2, most often with mild to moderate severity; however, metabolic acidosis can manifest earlier on in the course of Chronic Kidney Disease. Multiple animal and human studies have shown that metabolic acidosis in Chronic Kidney Disease, given its chronic nature, has a profound adverse impact on cellular function, overall contributing to high morbidities in patients.
The most adverse consequences of chronic metabolic acidosis in people with Chronic Kidney Disease and in particular, for those who have end-stage renal disease (ESRD), are detrimental changes to the bones and muscles.[29] Acid buffering leads to loss of bone density, resulting in an increased risk of bone fractures,[30] renal osteodystrophy,[31] and bone disease;[29] as well, increased protein catabolism leads to muscle wasting.[32][33] Furthermore, metabolic acidosis in Chronic Kidney Disease is also associated with a reduction in eGFR; it is both a complication of Chronic Kidney Disease, as well as an underlying cause of Chronic Kidney Disease progression.[34][35][36][37]
Treatment
Treatment of metabolic acidosis depends on the underlying cause, and should target reversing the main process. When considering course of treatment, it is important to distinguish between acute versus chronic forms.
Acute Metabolic Acidosis
Bicarbonate therapy is generally administered In patients with severe acute acidemia (pH < 7.11), or with less severe acidemia (pH 7.1-7.2) who have severe acute kidney injury. Bicarbonate therapy is not recommended for people with less severe acidosis (pH ≥ 7.1), unless severe acute kidney injury is present. In the BICAR-ICU trial,[1] bicarbonate therapy for maintaining a pH >7.3 had no overall effect on the composite outcome of all-cause mortality and the presence of at least one organ failure at day 7. However, amongst the sub-group of patients with severe acute kidney injury, bicarbonate therapy significantly decreased the primary composite outcome, and 28-day mortality, along with the need for dialysis.
Chronic Metabolic Acidosis
For people with Chronic Kidney Disease, treating metabolic acidosis slows the progression of chronic kidney disease.[38] Dietary interventions for treatment of chronic metabolic acidosis include base-inducing fruits and vegetables that assist with reducing the urine net acid excretion, and increase TCO2. Recent research has also suggested that dietary protein restriction, through ketoanalogue-supplemented vegetarian very low protein diets are also a nutritionally safe option for correction of metabolic acidosis in people with Chronic Kidney Disease.[39]
Currently, the most commonly used treatment for chronic metabolic acidosis is oral bicarbonate. The NKF/KDOQI guidelines recommend starting treatment when serum bicarbonate levels are <22 mEq/L, in order to maintain levels ≥ 22 mEq/L.[10][11] Studies investigating the effects of oral alkali therapy demonstrated improvements in serum bicarbonate levels, resulting in a slower decline in kidney function, and reduction in proteinuria – leading to a reduction in the risk of progressing to kidney failure. However, side effects of oral alkali therapy include gastrointestinal intolerance, worsening edema, and worsening hypertension. Furthermore, large doses of oral alkali are required to treat chronic metabolic acidosis, and the pill burden can limit adherence.[40]
Veverimer (TRC 101) is a promising investigational drug designed to treat metabolic acidosis by binding with the acid in the gastrointestinal tract and removing it from the body through excretion in the feces, in turn decreasing the amount of acid in the body, and increasing the level of bicarbonate in the blood. Results from a Phase 3, double-blind placebo-controlled 12-week clinical trial in people with CKD and metabolic acidosis demonstrated that Veverimer effectively and safely corrected metabolic acidosis in the short-term,[41] and a blinded, placebo-controlled, 40-week extension of the trial assessing long-term safety, demonstrated sustained improvements in physical function and a combined endpoint of death, dialysis, or 50% decline in eGFR.[42]
See also
- Delta ratio
- Metabolic alkalosis
- Respiratory acidosis
- Respiratory alkalosis
- Trauma triad of death
- Winters' formula
- Intravenous bicarbonate
References
- ^ a b Jaber, Samir; Paugam, Catherine; Futier, Emmanuel; et al. (2018). "Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial" (PDF). The Lancet. 392 (10141): 31–40. doi:10.1016/S0140-6736(18)31080-8. PMID 29910040. S2CID 49276138.
- ^ Navaneethan, Sankar D.; Shao, Jun; Buysse, Jerry; Bushinsky, David A. (5 July 2019). "Effects of Treatment of Metabolic Acidosis in CKD: A Systematic Review and Meta-Analysis". Clinical Journal of the American Society of Nephrology. 14 (7): 1011–1020. doi:10.2215/CJN.13091118. PMC 6625635. PMID 31196951.
- ^ Kraut, Jeffrey A.; Madias, Nicolaos E. (4 September 2012). "Treatment of acute metabolic acidosis: a pathophysiologic approach". Nature Reviews Nephrology. 8 (10): 589–601. doi:10.1038/nrneph.2012.186. PMID 22945490. S2CID 34657707.
- ^ Jung, Boris; Rimmele, Thomas; Le Goff, Charlotte; Chanques, Gérald; Corne, Philippe; Jonquet, Olivier; Muller, Laurent; Lefrant, Jean-Yves; Guervilly, Christophe; Papazian, Laurent; Allaouchiche, Bernard; Jaber, Samir (2011). "Severe metabolic or mixed acidemia on intensive care unit admission: incidence, prognosis and administration of buffer therapy. A prospective, multiple-center study". Critical Care (London, England). 15 (5): R238. doi:10.1186/cc10487. PMC 3334789. PMID 21995879.
- ^ Inker, Lesley A.; Coresh, Josef; Levey, Andrew S.; Tonelli, Marcello; Muntner, Paul (1 December 2011). "Estimated GFR, Albuminuria, and Complications of Chronic Kidney Disease". Journal of the American Society of Nephrology. 22 (12): 2322–2331. doi:10.1681/ASN.2010111181. PMC 3279937. PMID 21965377.
- ^ a b c Emmett, Michael; Szerlip, Harold. "Approach to the adult with metabolic acidosis".
- ^ Costanzo, Linda (2010). Physiology. Philadelphia, Pennsylvania: Elsevier. ISBN 978-1-4160-6216-5.
- ^ a b Kraut, Jeffrey A.; Madias, Nicolaos E. (2010-05-01). "Metabolic acidosis: pathophysiology, diagnosis and management". Nature Reviews Nephrology. 6 (5): 274–285. doi:10.1038/nrneph.2010.33. ISSN 1759-5061. PMID 20308999. S2CID 205512465.
- ^ Gallo de Moraes, Alice; Surani, Salim (2019-01-15). "Effects of diabetic ketoacidosis in the respiratory system". World Journal of Diabetes. 10 (1): 16–22. doi:10.4239/wjd.v10.i1.16. ISSN 1948-9358. PMC 6347653. PMID 30697367.
- ^ a b "National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease" (PDF). Am J Kidney Dis. 42 (Suppl 3): S1–S201.
- ^ a b "CKD Evaluation and Management – KDIGO". kdigo.org. Retrieved 2019-12-31.
- ^ Weaver, Connie M. (2013-05-06). "Potassium and Health123". Advances in Nutrition. 4 (3): 368S–377S. doi:10.3945/an.112.003533. ISSN 2161-8313. PMC 3650509. PMID 23674806.
- ^ Kovesdy, Csaba. "Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease". UpToDate.
- ^ Stern, Scott D. C.; Cifu, Adam S.; Altkorn, Diane (2015). Symptom to diagnosis: an evidence-based guide (3rd ed.). New York: McGraw-Hill Education. ISBN 9780071803441. OCLC 896866189.
- ^ Quinn, Gene R.; Gleason, Nathaniel W.; Papadakis, Maxine A.; McPhee, Stephen J., eds. (2016). Current medical diagnosis & treatment study guide (2nd ed.). New York: McGraw-Hill. ISBN 9780071848053. OCLC 910475681.
- ^ a b DeGowin's diagnostic examination. LeBlond, Richard F.,, Brown, Donald D., 1940-, Suneja, Manish,, Szot, Joseph F. (Tenth ed.). New York. 2014-09-05. ISBN 9780071814478. OCLC 876336892.
{{cite book}}
: CS1 maint: others (link) - ^ Morgan & Mikhail's clinical anesthesiology. Butterworth, John F., IV,, Mackey, David C.,, Wasnick, John D.,, Morgan, G. Edward,, Mikhail, Maged S.,, Morgan, G. Edward. (Sixth ed.). New York. 2018-08-21. ISBN 9781259834424. OCLC 1039081701.
{{cite book}}
: CS1 maint: others (link) - ^ Poisoning and drug overdose. Olson, Kent R. (Kent Russell),, Anderson, Ilene B.,, Benowitz, Neal L.,, Blanc, Paul D., 1951-, Clark, Richard F.,, Kearney, Thomas E. (Seventh ed.). [New York]. 15 December 2017. ISBN 9780071839808. OCLC 1013928560.
{{cite book}}
: CS1 maint: others (link) - ^ Critical care. Oropello, John M.,, Pastores, Stephen M.,, Kvetan, Vladimir. [New York]. 2016-11-22. ISBN 9780071817264. OCLC 961480454.
{{cite book}}
: CS1 maint: others (link) - ^ Current medical diagnosis & treatment 2020. Papadakis, Maxine A.,, McPhee, Stephen J.,, Rabow, Michael W. (Fifty-eighth ed.). New York. 2019-09-02. ISBN 9781260455281. OCLC 1109935506.
{{cite book}}
: CS1 maint: others (link) - ^ Harrison's principles of internal medicine. Jameson, J. Larry,, Kasper, Dennis L.,, Longo, Dan L. (Dan Louis), 1949-, Fauci, Anthony S., 1940-, Hauser, Stephen L.,, Loscalzo, Joseph (20th ed.). New York. 2018-08-13. ISBN 9781259644030. OCLC 1029074059.
{{cite book}}
: CS1 maint: others (link) - ^ Morgan & Mikhail's clinical anesthesiology. Butterworth, John F., IV,, Mackey, David C.,, Wasnick, John D.,, Morgan, G. Edward,, Mikhail, Maged S.,, Morgan, G. Edward. (Sixth ed.). New York. 2018-08-21. ISBN 978-1259834424. OCLC 1039081701.
{{cite book}}
: CS1 maint: others (link) - ^ Katzung, Bertram G. (2018-09-05). Katzung & Trevor's pharmacology : examination & board review. Kruidering-Hall, Marieke,, Trevor, Anthony J. (Twelfth ed.). New York. ISBN 978-1259641022. OCLC 1052466341.
- ^ Levitzky, Michael G. (2007). Pulmonary physiology (7th ed.). New York: McGraw-Hill Medical. ISBN 9780071437752. OCLC 75713147.
- ^ Field, Michael J.; Pollock, Carol A.; Harris, David C. (2010). The renal system: basic science and clinical conditions (2nd ed.). Edinburgh: Churchill Livingstone/Elsevier. ISBN 9780702033711. OCLC 319855752.
- ^ Meert, K. L; Clark, J; Sarnaik, A. P (2007). "Metabolic acidosis as an underlying mechanism of respiratory distress in children with severe acute asthma". Pediatric Critical Care Medicine. 8 (6): 519–23. doi:10.1097/01.PCC.0000288673.82916.9D. PMID 17906597. S2CID 27488853.
- ^ Costanzo, Linda S. (2017-03-15). Physiology (6th ed.). Philadelphia, PA: Elsevier. ISBN 9780323511896. OCLC 965761862.
- ^ Kraut, Jeffrey A.; Madias, Nicolaos E. (4 September 2012). "Treatment of acute metabolic acidosis: a pathophysiologic approach". Nature Reviews Nephrology. 8 (10): 589–601. doi:10.1038/nrneph.2012.186. PMID 22945490. S2CID 34657707.
- ^ a b Kraut, Jeffrey A.; Madias, Nicolaos E. (2017). "Adverse Effects of the Metabolic Acidosis of Chronic Kidney Disease". Advances in Chronic Kidney Disease. 24 (5): 289–297. doi:10.1053/j.ackd.2017.06.005. PMID 29031355.
- ^ Kato, Akihiko; Kido, Ryo; Onishi, Yoshihiro; Kurita, Noriaki; Fukagawa, Masafumi; Akizawa, Tadao; Fukuhara, Shunichi (2014). "Association of serum bicarbonate with bone fractures in hemodialysis patients: the mineral and bone disorder outcomes study for Japanese CKD stage 5D patients (MBD-5D)". Nephron Clinical Practice. 128 (1–2): 79–87. doi:10.1159/000365089. ISSN 1660-2110. PMID 25378374. S2CID 20320396.
- ^ Lefebvre, A.; de Vernejoul, M. C.; Gueris, J.; Goldfarb, B.; Graulet, A. M.; Morieux, C. (1989). "Optimal correction of acidosis changes progression of dialysis osteodystrophy". Kidney International. 36 (6): 1112–1118. doi:10.1038/ki.1989.309. ISSN 0085-2538. PMID 2557481.
- ^ Hanna, Ramy M.; Ghobry, Lena; Wassef, Olivia; Rhee, Connie M.; Kalantar-Zadeh, Kamyar (2020). "A Practical Approach to Nutrition, Protein-Energy Wasting, Sarcopenia, and Cachexia in Patients with Chronic Kidney Disease". Blood Purification. 49 (1–2): 202–211. doi:10.1159/000504240. ISSN 0253-5068. PMID 31851983. S2CID 209418220.
- ^ Foley, Robert N.; Wang, Changchun; Ishani, Areef; Collins, Allan J.; Murray, Anne M. (2007). "Kidney Function and Sarcopenia in the United States General Population: NHANES III". American Journal of Nephrology. 27 (3): 279–286. doi:10.1159/000101827. ISSN 0250-8095. PMID 17440263. S2CID 2847009.
- ^ Shah, Samir N.; Abramowitz, Matthew; Hostetter, Thomas H.; Melamed, Michal L. (2009-08-01). "Serum bicarbonate levels and the progression of kidney disease: a cohort study". American Journal of Kidney Diseases. 54 (2): 270–277. doi:10.1053/j.ajkd.2009.02.014. ISSN 1523-6838. PMC 4354889. PMID 19394734.
- ^ Dobre, Mirela; Yang, Wei; Chen, Jing; Drawz, Paul; Hamm, L. Lee; Horwitz, Edward; Hostetter, Thomas; Jaar, Bernard; Lora, Claudia M.; Nessel, Lisa; Ojo, Akinlolu (2013-10-01). "Association of Serum Bicarbonate With Risk of Renal and Cardiovascular Outcomes in CKD: A Report From the Chronic Renal Insufficiency Cohort (CRIC) Study". American Journal of Kidney Diseases. 62 (4): 670–678. doi:10.1053/j.ajkd.2013.01.017. ISSN 0272-6386. PMC 3701754. PMID 23489677.
- ^ Menon, Vandana; Tighiouart, Hocine; Vaughn, Nubia Smith; Beck, Gerald J.; Kusek, John W.; Collins, Allan J.; Greene, Tom; Sarnak, Mark J. (2010-11-01). "Serum Bicarbonate and Long-term Outcomes in CKD". American Journal of Kidney Diseases. 56 (5): 907–914. doi:10.1053/j.ajkd.2010.03.023. ISSN 0272-6386. PMID 20605301.
- ^ Raphael, Kalani L.; Wei, Guo; Baird, Bradley C.; Greene, Tom; Beddhu, Srinivasan (2011-02-01). "Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans". Kidney International. 79 (3): 356–362. doi:10.1038/ki.2010.388. ISSN 0085-2538. PMC 5241271. PMID 20962743.
- ^ Goraya, Nimrit; Wesson, Donald E. (2019). "Clinical evidence that treatment of metabolic acidosis slows the progression of chronic kidney disease". Current Opinion in Nephrology and Hypertension. 28 (3): 267–277. doi:10.1097/MNH.0000000000000491. ISSN 1062-4821. PMC 6467553. PMID 30681417.
- ^ Garneata, Liliana; Stancu, Alexandra; Dragomir, Diana; Stefan, Gabriel; Mircescu, Gabriel (2016-07-01). "Ketoanalogue-Supplemented Vegetarian Very Low–Protein Diet and CKD Progression". Journal of the American Society of Nephrology. 27 (7): 2164–2176. doi:10.1681/ASN.2015040369. ISSN 1046-6673. PMC 4926970. PMID 26823552.
- ^ Chen, Wei; Abramowitz, Matthew K. (2019). "Advances in management of chronic metabolic acidosis in chronic kidney disease". Current Opinion in Nephrology and Hypertension. 28 (5): 409–416. doi:10.1097/MNH.0000000000000524. ISSN 1473-6543. PMC 6677263. PMID 31232712.
- ^ Wesson, Donald E.; Mathur, Vandana; Tangri, Navdeep; Stasiv, Yuri; Parsell, Dawn; Li, Elizabeth; Klaerner, Gerrit; Bushinsky, David A. (2019-04-06). "Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial". The Lancet. 393 (10179): 1417–1427. doi:10.1016/S0140-6736(18)32562-5. ISSN 0140-6736. PMID 30857647. S2CID 72332908.
- ^ Wesson, Donald E.; Mathur, Vandana; Tangri, Navdeep; Stasiv, Yuri; Parsell, Dawn; Li, Elizabeth; Klaerner, Gerrit; Bushinsky, David A. (2019-08-03). "Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension". The Lancet. 394 (10196): 396–406. doi:10.1016/S0140-6736(19)31388-1. ISSN 0140-6736. PMID 31248662. S2CID 195339720.